Gedatolisib (revtorpyk): Treatment Discussion Guide
Last Updated: October 1, 2026
Supporting Coordinated Care in Advanced Breast Cancer
Preparing patients for treatment involves the entire medically integrated oncology team, from discussing treatment options to coordinating medications, monitoring side effects, and addressing access barriers. NCODA’s Gedatolisib (REVTORPYK™) Treatment Discussion Guide brings these responsibilities together to support care for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Organized for physicians, advanced practice providers, nurses, pharmacists, and pharmacy technicians, the guide pairs practical patient discussion prompts with role-specific responsibilities. It addresses gedatolisib-based therapy with fulvestrant, with or without palbociclib, covering patient selection, treatment readiness, administration, supportive care, and ongoing monitoring.
Key Features of the Guide Include:
- Role-Specific Questions & Responsibilities
Focused considerations and discussion prompts help each team member prepare patients for treatment, reinforce education, and coordinate care throughout therapy. - Practical Patient Education & Safety Considerations
Guidance covers treatment schedules, supportive medications, stomatitis and rash prevention, blood glucose monitoring, and recognizing symptoms that require prompt communication with the care team. - Medication Access & Treatment Continuity
Pharmacy technician sections address benefits investigations, prior authorizations, prescription coordination, refill planning, and patient support resources to help identify and resolve barriers before they interrupt treatment. - Ongoing Support for Quality of Life
Prompts help teams assess how treatment affects daily activities, medication adherence, emotional well-being, and supportive care needs, with references to NCODA’s Patient Treatment Calendar and Positive Quality Intervention resources.
Use the guide to structure treatment conversations, clarify team responsibilities, and reinforce consistent education from the first treatment discussion through ongoing follow-up.
Download the Gedatolisib (REVTORPYK™) Treatment Discussion Guide to support patient education and coordinated care across your oncology team.